戻る Agenda
[S44] Innovative Drug Development: Is the Placebo Arm Really Necessary?
Session Chair(s)
Haruko Yamamoto, MD, PhD
Executive Director
National Cerebral and Cardiovascular Center, Japan
Since long ago, clinical trials have been conducted using a placebo arm in drug development. The meaning of setting the placebo arm as the theory of clinical trial design is well established and understood among those involved in drug development. On the other hand, it is also a fact that the clinical trial sites or patients have a sense that “it is difficult to conduct a trial with a placebo arm”, “does not want to receive a placebo”, which makes difficult to conduct the clinical trials. In this session, we asked the question, “Is the placebo arm really necessary?”, Referring to the state of the anticancer drug, and receiving opinions from doctors, patients, industries, and regulators in Japan and overseas viewpoints, discuss the possibility of clinical development without putting placebo arm.
Speaker(s)
Oncology Experience
Taro Shibata, MSc
Center for Research Administration and Support, National Cancer Center, Japan
Chief, Biostatistics Division
Patient View
Yoshiyuki Majima
Rare Cancers Japan, Japan
President
Innovative Drug Development: Is The Placebo Arm Really Necessary?
Dalvir Gill, PhD
TransCelerate BioPharma Inc., United States
Chief Executive Officer
Agnès Saint-Raymond, DrMed
European Medicines Agency, Netherlands
Head of Division International Affairs